Investor Outlook: Significance of the Positive LCA2 Gene Therapy Phase III Results

Human Gene Therapy Clinical Development

Volumn 26, Issue 4, 2015, Pages 208-210

  Schimmer, Joshua ^a   Breazzano, Steven ^a  

^a Piper Jaffray Company   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE THERAPY AGENT; RETINAL PIGMENT EPITHELIUM SPECIFIC PROTEIN 65KDA; UNCLASSIFIED DRUG; CIS TRANS ISOMERASE; RETINOID ISOMEROHYDROLASE;

ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; GENE THERAPY; HUMAN; INTENTION TO TREAT ANALYSIS; LEBER CONGENITAL AMAUROSIS; LEBER CONGENITAL AMAUROSIS TYPE 2; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA DISEASE; TREATMENT RESPONSE; UNITED STATES; VISUAL ACUITY; VISUAL IMPAIRMENT; ADVERSE EFFECTS; ECONOMICS; GENETICS; INVESTMENT; PROCEDURES;

CIS-TRANS-ISOMERASES; CLINICAL TRIALS, PHASE III AS TOPIC; GENETIC THERAPY; HUMANS; INVESTMENTS; LEBER CONGENITAL AMAUROSIS;

EID: 85006208844     PISSN: 23248637     EISSN: 23248645     Source Type: Journal    
DOI: 10.1089/humc.2015.29004.sch     Document Type: Article

References (2)

1. Schimmer J, Breazzano S. Investor outlook: Focus on upcoming LCA2 gene therapy phase III results. Hum Gene Ther Clin Dev 2015; 26: 144-149.
2. Spark Therapeutics. Spark Therapeutics investor relations. http: //ir.sparktx.com (last accessed December 4, 2015).